Tranzyme Pharma’s oral gastrointestinal (GI) prokinetic drug candidate TZP-102, for the treatment of gastroparesis in diabetic patients, was granted Fast Track designation from the FDA. Gastroparesis is a serious complication of diabetes mellitus that affects approximately 30-60% of diabetic patients. Fast track designation is designed to facilitate the development and expedite the review of a drug candidate that treats a serious or life-threatening condition and addresses an unmet medical ne...